Glycemic effects of simvastatin: Where do we stand?
Braz. J. Pharm. Sci. (Online)
;
54(1): e17192, 2018. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-951911
ABSTRACT
ABSTRACT In clinical practice, simvastatin is usually used in the treatment of dyslipidemia patients and those at risk of or with established cardiovascular disease. However, previous studies have shown that simvastatin has the potential to affect glycemic parameters as it reportedly reduced insulin secretion and sensitivity. The exact mechanism by which simvastatin affects glycemia is still unknown, but previous studies have postulated the involvement of the glucose-insulin secretion mechanism. This review focuses on the effects of simvastatin, either alone or in combination with other lipid lowering agents, antidiabetics and antihypertensives, on glucose homeostasis. Some studies have reported that simvastatin might impair the levels of glucose metabolism markers in the blood while others have reported no effect or improvement in glycemia.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Simvastatina
/
Interacciones Farmacológicas
/
Glucosa
/
Antagonistas de Insulina
Idioma:
Inglés
Revista:
Braz. J. Pharm. Sci. (Online)
Asunto de la revista:
Farmacologia
/
Teraputica
/
Toxicologia
Año:
2018
Tipo del documento:
Artículo
/
Documento de proyecto
País de afiliación:
Malasia
Institución/País de afiliación:
University Malaya Medical Centre/MY
/
University of Malaya/MY
Similares
MEDLINE
...
LILACS
LIS